Introduction
Salbutamol is a β2-mimetic used as a bronchodilator which is presented as the (±) racemic mixture in pharmaceutical inhalers (propellant-based and dry powder), nebules, injections, syrups and tablets, including controlled-release forms 1 . The hemisulfate salt (commonly referred to as salbutamol sulfate) is the most common form of salbutamol used in pharmaceutical products however the (R) salbutamol hydrochloride form is also available on the market as an inhalation solution (Xopenex TM , manufactured by Sepracor Inc.). Although some other salbutamol salts have been reported in the literature, e.g. ethanolated salbutamol adipate and salbutamol stearate 2 , to date only two crystal structures are reported in the Cambridge Structural Database: salbutamol base (SB) 3 and salbutamol sulfate (SS) 4 . The information about the solid state nature of other forms of salbutamol is sparse.
From a pharmaceutical point of view, different solid-state characteristics of salt forms can result in different in vitro solubility and dissolution properties, which in turn can result in an alteration of the in vivo activity of the active pharmaceutical ingredient (API). In particular, for pulmonary delivery, possibilities for modification of the dissolution profile of the API from a formulation point of view are limited, due to restrictions in terms of the excipients that are regarded as safe for pulmonary use, and may result in additional costs and regulatory obstacles associated with the development of a new drug product. This may be avoided by the direct production of alternative crystalline forms of the API with the desired solubility and dissolution profiles. The marketed solid dosage forms contain only SS, which is freely soluble in water 5 . The advantage of prolonged release tablets containing SS was reported in clinical studies 6 . New prolonged release oral dosage forms containing SS include hard capsules VentMax TM and tablet forms: Volmax CR TM , Vospire ER TM 7 . Both, prolonged release capsules and tablets containing SS have monographs in the British Pharmacopeia 8 . A transdermal delivery patch of SS was also developed 9 .
In this study we investigated the impact of replacing the sulfate anion in the SS salt structure by an organic dicarboxylic acid, either the four-carbon chain, succinic (butanedioic) acid or the six-carbon chain, adipic (hexanedioic) acid, on the physicochemical characteristics of the API. These two organic acids were chosen in order to investigate the impact of small changes in the chemical structure of the coformer on the physicochemical properties of the resulting salbutamol forms. A reasonable correlation between the melting points of organic co-formers and melting points of the resulting salts was previously reported for diclofenac 10 . The authors also observed a trend between the salt melting point and the logarithm of the solubility. The reported melting points of adipic and succinic acids are ~151-154 ˚C and ~185-187 ˚C, respectively 11 , hence it may be hypothesized that the succinate would have a lower solubility than that of the adipate. On the other hand, increasing the hydrophilicity of the counterion as a means of increasing the water solubility of the resultant salt has been proposed and investigated for a series of erythromycin 12 . The calculated logPs of adipic and succinic acid are 0.356 and -0.655 respectively 13 , indicating that a salt of adipic acid may be less soluble than that of succinic acid. The study performed by Lee at al. 14 successfully investigated the possibility of forming ionic (salts) or neutral (co-crystals) complexes of a heterocyclic base (an ErbB2 inhibitor for the treatment of cancer) with dicarboxylic acids comprising succinate, malonate and maleate co-formers. The acids (adipic and succinic) used in the current study have similar pKa values. The pKa1 and pKa2 for succinic acid are 4.21 and 5.64 11 and for adipic acid these are 4.44 and 5.44 11 . As pKas of salbutamol are 9.1 and 10.4 15 , it was expected that the new forms of the API would be novel 1:1 salts of salbutamol.
Both acids are classified by the U.S. Food and Drug Administration as Generally Recognised As Safe (GRAS) 16, 17 and listed in the European Pharmacopeia 5 . Adipic acid is currently used to produce salts of piperazine (Entacyl TM ) and spiramycine (Rovamycine TM injectable form) 11 . Succinic acid is used to form salts of e.g. benfurodil, bamethan, chloramphenicol, cibenzoline, deanol, doxylamine, ergotamine, loxepine, metoprolol, oxaflumazine, sumatriptan and iron (FeII) 11 .
Materials
Salbutamol base was obtained from CHEMOS GmbH Germany. Adipic acid was obtained from Sigma- 
Methods

Crystallization studies
Attempts were made to crystallize salbutamol with adipic acid and succinic acid by solvent evaporation from ethanol, methanol and water. The tested molar ratios of salbutamol to the acid were: 1:2, 1:1 and 2:1 for each solvent. It was observed that successful crystallization was achieved only for salbutamol mixed with adipic acid in the 1:1 molar ratio using methanol or water as the solvent and for salbutamol and succinic acid mixed in the 2:1 molar ratio using methanol (details of the procedure are described below). Other combinations resulted either in crystallization of one or two of the components separately or in the production of a glassy/amorphous material.
The crystals subsequently used for single crystal X-ray and other analyses were prepared from saturated solutions, which were obtained by introducing an excess of raw material into the appropriate solvent at ambient conditions and shaking for an hour on a WhirliMixer ® (Fisons Scientific Equipment). 10 mL of the suspension obtained was filtered through a 0.22 µm membrane filter into a glass vial which was kept in a glove box (Clean Sphere CA 100, Safetech Limited) under constant nitrogen flow at room temperature (20-23 ˚C) . The moisture content in this controlled environment was less than 1% relative humidity.
Dry nitrogen flow and temperature control were provided to maintain reproducible conditions of solvent evaporation. Crystallization of SA from methanol resulted each time in a very rapid nucleation of the crystals. Modification of the environmental conditions, including slowing down the evaporation rate of methanol and decreasing the temperature, did not retard the crystal growth. Very small crystals with crystal defects (inclusions) were not of sufficiently good quality to be analyzed by single crystal X-ray analysis. A change of the solvent to water resulted in slow crystal growth and good quality crystals of SA, with a PXRD pattern consistent with that obtained for crystals produced from methanol, hence the SA crystals obtained from water were later used for single crystal X-ray analysis.
Preparation of salbutamol adipate and succinate
A stoichiometric mixture of salbutamol and adipic acid in a 1:1 molar ratio was dissolved in methanol at 0.05 g/mL concentration of solid at 25 ˚C. Methanol was evaporated under forced air flow at an evaporation rate 0.4 g/min (monitored using a balance every 5 min), whilst stirring. The white precipitate was filtered close to the end of methanol evaporation. The precipitate was dried for an hour under constant air flow at 25 ˚C. The dry powder was subjected to elemental analysis and was determined to be salbutamol mono adipate (SA). It was obtained with a 95% yield.
A stoichiometric mixture of salbutamol and succinic acid in a 2:1 molar ratio was dissolved in methanol at 0.05 g/mL concentration of solid at 25 ˚C. Methanol was evaporated under forced air flow at an evaporation rate of 0.4 g/min (monitored using a balance every 5 min), whilst stirring. After nucleation of the salt, the temperature was dropped to 20 ˚C and the evaporation rate of methanol was kept constant (0.4 g/min) until the concentration of solid in methanol reached 0.1 g/mL. 
Differential scanning calorimetry (DSC)
DSC experiments were performed using a Mettler Toledo DSC 821 e with a refrigerated cooling system, LabPlant RP-100. Nitrogen was used as the purge gas. Aluminium sample holders were sealed with a lid and pierced to provide three vent holes. Sample volume was sufficient to provide proper contact between the powder and the bottom of the pan, and sample weight was ≥5 mg. DSC measurements were carried out at a heating/cooling rate of 10 ˚C/min 21 
Elemental analysis
Elemental analysis was carried out using an Exeter Analytical CE440 CHN analyzer. The molar amount of carbon as carbon dioxide, nitrogen, as nitrogen oxide and hydrogen as water, was determined by oxidation of the sample (around 10 mg) and thermal conductivity analysis of the gases obtained 23 .
Dynamic vapor sorption (DVS)
Vapor sorption experiments were performed on a DVS Advantage-1 automated gravimetric vapor sorption analyzer (Surface Measurement Systems Ltd., London, UK). The temperature was maintained constant at 25.0 ± 0.1 °C. A mass of around 10 mg of powder was loaded into a sample net basket and placed in the system. The samples were equilibrated at 0% of relative humidity (RH) until the dry, reference mass was recorded. The samples were exposed to the following % of RH profile: 0 to 90% in 10% steps and the same for desorption. At each stage, the sample mass was equilibrated (dm/dt ≤ 0.002 mg/min for at least 10 min) before the change of relative humidity. An isotherm was calculated from the complete sorption and desorption profile. Amount of water was expressed as a percentage of the reference mass.
Specific surface area analysis (T BET ) by Brunauer, Emmett, Teller (BET) isotherm
Samples were dried prior to analysis under nitrogen flow at 50˚C for 12 hours using a Gemini SmartPrep (USA) drying station. To determine the bulk specific surface area a Micromeritics Gemini VI (USA) surface area analyzer was used. Compressed nitrogen was used as an adsorptive gas. Each measurement consisted of six steps, determining the amount of gas adsorbed at 6 relative pressure points in the range of 0.05 to 0.3 of relative pressure P/P 0 with equilibration time of 10s. Free space was determined separately for each sample using helium gas. Saturation pressure P o was determined prior to the measurement of each sample.
Particle size
Measurements of particle size and particle size distributions were obtained using a laser diffraction particle sizer Mastersizer 2000 (Malvern Instruments, UK). Particles were dispersed using a Scirocco dry feeder instrument with 2 bar pressure. An obscuration rate of 0.5-6% was obtained under a vibration feed rate of 50%.
Solubility studies
Powdered SA, SSU and SB were added in excess (approximately three times the expected saturated concentration of salbutamol) directly to 2 ml of water in an Eppendorf vial at 37 ˚C 24 . Additionally, the SA powder was suspended in a NaOH solution to investigate its solubility at a pH value other than that measured for the sample in pure water. The Eppendorfs were placed horizontally in a water bath and shaken at 100 cpm. Suspensions were filtered through a 0.22 µm membrane filter. The content of salbutamol in the saturated solutions was assayed by UV spectrophotometry at 276 nm (Shimadzu UV 1700 Pharmaspec). SB, SA and SSU aliquots were diluted with water to obtain the appropriate concentration range. Samples were withdrawn and analyzed after 10, 11 and 12 hours and as equilibrium appeared to be reached after 10 hours, the values were averaged over these three time points.
The content of adipic and succinic acids in SA and SSU aliquots was determined with a high pressure liquid chromatography (HPLC). The HPLC system used was a Shimadzu HPLC Class VP series with a LC-10AT VP pump, autosampler SIL-10AD VP and SCL-10AVP system controller. The mobile phase was filtered through a 0.45 μm membrane filter (Gelman Supor-450, USA) before use. The HPLC method used for the analysis of the dicarboxylic acids was modified from Thoma and Ziegler 25 and
Kordis-Krapez et al. 26 . The analytical column used was a LiChrosorb RP-10 column (250 mm length, internal diameter 4 mm, particle size 10 μm). UV detection was carried out at a wavelength of 210 nm and the injection volume was 20 μL.
Separation of adipic acid was carried out isocratically at ambient temperatures with a flow rate of 1 ml/min. The mobile phase consisted of methanol:phosphoric acid solution (pH 2.1) 20:80 (v/v).
Separation of succinic acid was carried out using a gradient method with a flow rate of 1 ml/min. The mobile phase consisted of two eluents: (A) phosphoric acid solution (pH 2.1) and (B) methanol:phosphoric acid solution (pH 2.1) 20:80 (v/v). The following gradient was used: a linear gradient from 0 to 50% B over 7 min, then a linear gradient from 50 to 100% B over 1 min and this composition was maintained for 7 min. Then again a linear gradient from 100 to 0% B over 10 min was applied and the final mobile phase composition was continued for a further 5 min. Under these conditions the retention times of adipic acid and succinic were: 4.3 and 6.5 min, respectively.
Intrinsic dissolution studies
Discs of SS, SSU and SA were prepared by compressing 300 mg of the given material in an IR hydraulic press (PerkinElmer, UK). The 13 mm diameter discs had a 1.33 cm 2 top surface area. The bottom and side surfaces of the discs were coated with paraffin wax and mounted in the centre of the bottom of a standard dissolution vessel 27 . Each dissolution experiment was performed in triplicate, as long as the dissolving disc kept a visibly constant surface area.
Intrinsic dissolution studies were performed with a type 2 dissolution test apparatus (VanKel VK7000 dissolution test station) equipped with VK650 heater/circulator) 5 . The rotation speed of the paddle was set to 100 rpm. 900 mL of deionized, degassed water was used as the dissolution medium, equilibrated at 37 ˚C. To sample the dissolution medium a standard dissolution vessel was equipped with a medium recirculation system. The dissolution medium was constantly circulating using a LSMatec peristaltic pump fitted with a 0.45 µm filter through a 2 mm flow-through UV cuvette placed in a Cecil CE2020
UV-spectrophotometer set to 276 nm 28 . The rate of medium circulation was set to 25 mL/min and the pH of the aqueous medium was monitored using a Thermo Orion 420+ pH-meter.
Statistical analysis
Statistical analysis was carried out using Minitab™ statistical software, version 14 (Minitab Inc, USA).
Two sample t-tests were carried out at a significance level of 0.05, with a p-value less than 0.05 taken as indicating that the observed difference between the means was statistically significant, i.e. rejecting the null hypothesis.
Data analysis
ACD/Chem Sketch TM freeware was used to calculate theoretical element contributions for elemental analysis and partial polarizability volumes 29 .
Results and discussion
Single crystal X-ray analysis
Single crystal analysis of SA and salbutamol succinate SSU.MeOH was undertaken, of which details are shown in Table 1 . Crystals of SA are centrosymmetric, with both enantiomers present in the lattice. 
Analysis of hydrogen bond network
Analysis of the hydrogen bonds in SA (Table 2 ) reveals that the vast majority of these bonds occur between the hydroxyl groups on the salbutamol and the ionized adipic carboxylate. This carboxylate is also hydrogen bonded to the secondary amine group of salbutamol. The protonated adipic acid does not play a crucial role in the creation of the hydrogen bond network, with only one hydrogen bond to a hydroxyl group of the salbutamol molecule.
Interestingly, analysis of the hydrogen bonds in methanolated salbutamol succinate (Table 3) A comparison of the crystal packing of SSA (Fig. 2a,b) with SSU.MeOH (Fig. 2c,d ) indicates why SSA contains an "additional" protonated molecule of adipic acid. It can be seen that SSA molecules packing along the c axis (Fig. 2b) Previously, a co-crystal of the salt of the API with an unionized counterion was reported for the anticonvulsant drug valproic acid, where the API comprised co-crystalline form of sodium valproate salt with valproic acid 31 . The use of co-crystals in a similar manner to salts in order to alter the physicochemical properties of API has been comprehensively investigated [32] [33] [34] [35] [36] [37] [38] , though only one paper published so far reports on the co-existence of dianions and an unionized form of the acid in the same crystal lattice, similarly to what we have determined for SA, it was a hydrated crystal of escitalopram oxalate with oxalic acid 39 .
Hirshfeld surfaces analysis
Hirshfeld surfaces analysis ( 
Results of PXRD analysis
The theoretical powder pattern of SA generated from the single crystal X-ray analysis at 100 K ( Figure   4 a) is consistent with the powder XRD pattern of the bulk material determined at ambient conditions (Figure 4 b) . There are small differences between the two patterns, which most likely can be attributed to thermal anisotropic expansion of the lattice.
The bulk material consisted of colorless, transparent, rhomboidal, thin, plate-like crystals.
Results of PXRD analysis of SSU.MeOH (Fig. 5 b) are also consistent with the theoretical PXRD pattern (Fig. 5 a) . Again, small differences between the two patterns can be attributed to the different temperatures used for the experiments. Figure 8 c presents the PXRD pattern of desolvated SSU.
Broadening and lower intensity of the Bragg peaks may be indicative of damage to the crystal lattice. 40 .
NMR results
1 H NMR confirmed the presence of methanol in the crystal structure due to the methyl group (3.18 ppm), which was absent in the desolvated form. Slight shifts in peak positions between SB and salbutamol salt forms may be ascribed to interactions of molecules of dissolved APIs with DMSO.
Results of 13 C NMR analysis are listed in Table 5 . 
Stoichiometry and elemental analysis
Elemental analysis confirms the molar ratio of salbutamol and adipic acid in SA is 1:1 (Table 6 ).
Elemental analysis of SSU.MeOH correlates well with single crystal X-ray analysis data suggesting a ratio of two molecules of salbutamol to one molecule of succinic acid to four molecules of methanol, the presence of which in the crystallized material was confirmed by NMR analysis. Results for the solvated material have greater variation due to solvate instability at ambient conditions and methanol evaporation. Results of elemental analysis confirm that the molar ratio of salbutamol to succinic acid in SSU is 2:1.
Thermal analysis
Thermal analysis (TGA) of SA did not indicate a significant mass loss on drying at the beginning of the scan. Overall mass loss recorded during the TGA scan (Fig. 6 a) up to 100 ˚C was 0.94±0.03% of initial mass of the sample. DSC analysis of the material showed a single strong endothermal event (Fig. 6 d) related to melting with decomposition at 181.00±0.04 ˚C, correlating with the beginning of significant further mass loss in the TGA. The melting point of adipic was measured to be at 150.93±0.10 ˚C.
DSC analysis of SSU.MeOH (Fig. 6 e) indicated a large broad endotherm with an onset at 69.97±0.30
˚C and enthalpy of 139.43 J/g. These endothermal events correlated well with the sample mass loss due to liberation of methanol (Fig. 6 b) of 17.26±1.20 %. The theoretical content of solvated methanol was calculated to be 17.68%.
The onset of thermal decomposition after desolvation was recorded to be 179.23±0.10 ˚C and corresponded with further significant mass loss. In contrast, succinic acid melted at 185.90±0.21 ˚C.
There was a 0.80±0.02 % overall mass loss up to 100˚C in the TGA determined for SSU ( 
FT-IR analysis
The FTIR patterns of SA (Fig. 7 c) and SSU (Fig. 8 d) differ in comparison to spectra of the parent compounds ( Fig. 7 a, b, e) . The main difference between SSA, SSU and SB is the strong suppression of conjugated C=C stretching vibrations of benzene ring of salbutamol just above 1600 cm -1 and changes in the intensity of the carboxylic acid C=O stretch peaks. The stretching vibration of N-H band of salbutamol ( Fig. 7 e) recorded at 3300 cm -1 for SB was nearly completely suppressed and slightly shifted towards longer wavelengths in SSU (Fig. 7 d) indicating a complete ionization of the secondary amine group. In contrast, the N-H stretching vibration of the secondary amine group in SA (Fig. 7 c) is relatively noticeable with a strong shift to 3450 cm -1 . These observations agree with the single crystal X-ray data suggesting a co-crystal form of SA, where one out of two adipic acid molecules per two molecules of salbutamol base remains unionized, but strongly H-bonded to the secondary amine group of salbutamol. The co-crystal versus salt forms of salbutamol are clearly distinguishable by FTIR, where the broad stretching vibration of C=O of the acid in SSU has been completely suppressed, while the acidic carbonyl group vibration in SA remained highly visible with a slight shift towards longer wavelengths.
Dynamic Vapor Sorption (DVS)
Both SSU and SA do not adsorb more than 2% of moisture and under the conditions of dynamic vapor sorption analysis do not tend to form hydrates (Fig. 8) . Results of equilibration of SSU at any given RH%, regardless of whether assessed in the sorption or desorption stage, are similar to SS, and in both cases the amount of adsorbed liquid does not exceed 0.3% of initial sample mass at 90% RH. In the case of SA sample less than 1.6% of initial mass was adsorbed at 90% RH.
Since the moisture sorption behavior may be attributed to the powder surface area, the samples subjected to the DVS analysis were also characterized in terms of their specific surface area and particle size. The specific surface area (T BET ) of SS was measured to be 1.53±0.02 m 2 /g, that of SA was 1.81±0.02 m 2 /g and T BET of SSU was 2.26±0.06 m 2 /g. The median particle size determined was 8.09±0.18, 19.26±0.07 and 8.73±0.09 µm for SS, SA and SSU, respectively. It is possible, therefore, that the higher propensity of SA to sorb moisture may be due to the different particle size, but cannot be explained by the difference in the surface area. It is likely that other surface properties, such as surface energy, contribute to this effect and will be the subject of further studies.
Solubility and dissolution studies
The estimated aqueous solubilities of SA, SSU and SB were found to be 82±2 mg/ml (equivalent to 0.231±0.001 M of salbutamol) at pH 4.5±0.1, 334±13 mg/ml (equivalent to 1.183±0.045 M of salbutamol) at pH 6.6±0.1 and 2.63±0.09 mg/ml (equivalent to 0.0110±0.0004 M of salbutamol) at pH 10.0±0.1, respectively. Thus the improvement in solubility, compared to SB, was 21-and 108-fold for the drug presented as SA and SSU, respectively, indicating that SSU has a 5-fold greater solubility than SA.
As the new forms of salbutamol are composed of the drug and co-former that are able to ionize in solution, it is expected that the pH of the saturated medium may have a profound effect on the solubility of the compounds 11 . This was investigated for SA, as it was easier to change the pH for this compound due to the lower solubility in comparison to SSU. When the pH of medium was adjusted to 5.3, the solubility of SA was measured to be 60±1 mg/ml.
Equations describing the solubility of gabapentin/3-hydroxybenzoic acid cocrystal, 42 and carbamazepine and itraconazole cocrystals have been reported 43 . These models allow relationships between the pH and co-crystal solubility to be predicted knowing only the solubility product constant (K sp ) and acid dissociation constants of the cocrystal constituents (pK a s). Although the theoretically-derived models neglect nonidealities due to complexation and other specific interactions, very good agreements between the calculated and experimental values were observed 42, 43 . This approach was employed in this work as the authors suggest that cocrystal solubility and its pH relationship may be estimated from a single measurement 43 . Similar mathematical equations were therefore developed for the new salbutamol forms to predict their solubility-pH dependence and estimate the solubility difference in relation to the pure drug. The co-formers and the drug have acidic and amphoteric characteristics, respectively, therefore the previously reported equations were adapted, taking into consideration that each of the species has two pKa values and that the stoichiometry of the succinate form is 2:1. Combining the total acid and drug concentrations, the solubility of salbutamol adipate can be expressed as (Eq.7):
Eq. 7 where S cocrystal is cocrystal solubility, K a1,H2A and K a2,H2A are the first and second dissociation constants for the acid and K a1,S and K a2,S are the first and second dissociation constants for the drug.
Using a similar approach, the equation for salbutamol succinate, considering the 2:1 stoichiometry, is as follows (Eq. 8):
Eq. 8
The pK sp constants for salbutamol adipate and succinate, calculated using the aqueous solubility values, were 6.3 and 8.6, respectively. Substituting in pKa values as follows: pK a1 =4.44, pK a2 =5.44 for adipic acid 11 , pK a1 =4.21, pK a2 =5.64 for succinic acid 11 and pK a1 =9.1, pK a2 =10.4 for salbutamol 17 , the pHsolubility profiles derived from Eqs. 8 and 9 are presented in Fig. 9 . The theoretical models suggest that a minimum SA solubility occurs at pH around 5 and that of SSU at pH 7. Symmetry codes: (a)1-x, -y, 1-z; (b) 1-x, -y, 2-z; (c) -x, -y, 2-z; (d) 1+x, 1+y, -1+z; 
